title: Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
abstract: Although classical Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging. Furthermore, because the median age of the patients is in the mid-30s, the impact of early mortality on the number of years lost from productive life is remarkable. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities. New drugs and novel treatment strategies that are based on our understanding of the disease biology and signaling pathways are needed to improve treatment outcome for these patients. This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.
authors.affiliation: Department of Lymphoma/Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA. ayounes@mdanderson.org
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D000922:Immunotoxins / Q000627:therapeutic use; D007211:Indoles; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D000077767:Panobinostat; D011877:Radionuclide Imaging; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D018796:Immunoconjugates; D000922:Immunotoxins; D007211:Indoles; D009363:Neoplasm Proteins; D011956:Receptors, Cell Surface; D000079963:Brentuximab Vedotin; D000077767:Panobinostat